Why the study?
Medical costs for cardiovascular disease are increasing, but few economic evaluations or meta-analyses of medical cost versus patient outcome exist for cardiac rehabilitation.
Does cardiac rehabilitation improve cost-effectiveness and quality-adjusted life years in patients with coronary artery disease compared to usual care?
Does cardiac rehabilitation improve cost-effectiveness and quality-adjusted life years in patients with coronary artery disease compared to usual care?
Cardiac rehabilitation is a cost-effective intervention that significantly improves quality-adjusted life years in patients with coronary artery disease compared to usual care.
Supports broader CR access in CAD for value-based care; reinforces Level 1 evidence of cost-effectiveness.
BACKGROUND: Medical costs associated with cardiovascular disease are increasing considerably worldwide; therefore, an efficacious, cost-effective therapy which allows the effective use of medical resources is vital. There have been few economic evaluations of cardiac rehabilitation (CR), especially meta-analyses of medical cost versus patient outcome. METHODS: The target population in this meta-analysis included convalescent and comprehensive CR patients with coronary artery disease (CAD), the status most commonly observed postmyocardial infarction (MI). Here, we evaluated medical costs, quality-adjusted life year (QALY), cost-effectiveness, mortality, and life year (LY). Regarding cost-effectiveness analysis, we analyzed medical costs per QALY, medical costs per LY, and the incremental cost-utility ratio (ICUR). We then examined the differences in effects for the 2 treatment arms (CR vs. usual care (UC)) using the risk ratio (RR) and standardized mean difference (SMD). RESULTS: We reviewed 59 studies and identified 5 studies that matched our selection criteria. In total, 122,485 patients were included in the analysis. Meta-analysis results revealed that the CR arm significantly improved QALY (SMD: -1.78; 95% confidence interval (CI): -2.69, -0.87) compared with UC. Although medical costs tended to be higher in the CR arm compared to the UC arm (SMD: 0.02; 95% CI: -0.08, 0.13), cost/QALY was significantly improved in the CR arm compared with the UC arm (SMD: -0.31; 95% CI: -0.53, -0.09). The ICURs for the studies (4 RCTs and 1 model analysis) were as follows: -48,327.6 USD/QALY; -5,193.8 USD/QALY (dominant, CR is cheaper and more effective than UC); and 4,048.0 USD/QALY, 17,209.4 USD/QALY, and 26,888.7 USD/QALY (<50,000 USD/QALY, CR is costlier but more effective than UC), respectively. Therefore, there were 2 dominant and 3 effective results. CONCLUSIONS: While there are some limitations, primarily regarding data sources, our results suggest that CR is potentially cost-effective.
No takes yet. Share an insight, caveat, or question.
Takura et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: